Kentucky Wight Loss Drug Attorney
US$ 27.53
dual glp-1/gip agonist GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes | Acta Diabetologica Targeting GLP-1, GIP & GCG
Description
SGLT2 inhibitors, a related medication, were initially approved for diabetes, but then subsequently had indications added for heart failure and chronic kidney disease
Marks 2018)
Cochrane Database of Systematic Reviews 2020
GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects
Two typical scenarios illustrate the directional conclusions of this model: Metabolism-driven: for patients with BMI 35 kg/m 2 , significant IR, and no near-term fertility plans, w 2 typically dominates
doi: 10.1038/nature11808